Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126517051 | 12651705 | 1 | I | 201304 | 20160802 | 20160815 | 20160815 | EXP | CH-HQ SPECIALTY-CH-2016INT000813 | INTERCHEM | LEUVENINK R, AESCHLIMANN F, BAER W, BERTHET G, CANNIZZARO E, HOFER M, ET AL.. CLINICAL COURSE AND THERAPEUTIC APPROACH TO VARICELLA ZOSTER VIRUS INFECTION IN CHILDREN WITH RHEUMATIC AUTOIMMUNE DISEASES UNDER IMMUNOSUPPRESSION. PEDIATR-RHEUMATOL. 2016;(34):1-6 | 7.00 | YR | M | Y | 0.00000 | 20160815 | MD | CH | CH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126517051 | 12651705 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Unknown | UNK | U | 201749 | |||||||||
| 126517051 | 12651705 | 2 | SS | INFLIXIMAB | INFLIXIMAB | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126517051 | 12651705 | 1 | Juvenile idiopathic arthritis |
| 126517051 | 12651705 | 2 | Juvenile idiopathic arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126517051 | 12651705 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126517051 | 12651705 | Varicella zoster virus infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |